Eliem Therapeutics, Inc. Stock price

Equities

ELYM

US28658R1068

Biotechnology & Medical Research

Delayed Nasdaq 02:14:47 2024-03-28 pm EDT 5-day change 1st Jan Change
2.786 USD +0.93% Intraday chart for Eliem Therapeutics, Inc. +2.04% +3.18%
Sales 2021 - Sales 2022 - Capitalization 97.5M
Net income 2021 -47M Net income 2022 -45M EV / Sales 2021 -
Net cash position 2021 161M Net cash position 2022 123M EV / Sales 2022 -
P/E ratio 2021
-2.46 x
P/E ratio 2022
-2.13 x
Employees 37
Yield 2021 *
-
Yield 2022
-
Free-Float 73.93%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.91%
1 week+2.04%
Current month+2.04%
1 month+2.04%
3 months+2.04%
6 months+6.33%
Current year+3.18%
More quotes
1 week
2.70
Extreme 2.7
2.93
1 month
2.54
Extreme 2.54
2.93
Current year
2.54
Extreme 2.54
2.98
1 year
2.34
Extreme 2.34
3.72
3 years
2.21
Extreme 2.21
29.69
5 years
2.21
Extreme 2.21
29.69
10 years
2.21
Extreme 2.21
29.69
More quotes
Managers TitleAgeSince
Founder 55 18-10-17
Chief Executive Officer 47 18-10-17
Chief Tech/Sci/R&D Officer 65 -
Members of the board TitleAgeSince
Director/Board Member 60 19-09-30
Director/Board Member 54 20-09-30
Chief Executive Officer 47 18-10-17
More insiders
Date Price Change Volume
24-03-28 2.786 +0.93% 2 363
24-03-27 2.76 +1.85% 3,570
24-03-26 2.71 -2.17% 1,785
24-03-25 2.77 -1.42% 14,700
24-03-22 2.81 +2.93% 3,755

Delayed Quote Nasdaq, March 28, 2024 at 02:14 pm EDT

More quotes
Eliem Therapeutics, Inc. is a biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. It is developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with therapeutic potential to deliver improved therapeutics for patients with these disorders. Its lead program is ETX-123, a Kv7.2/3 potassium channel opener. Kv7.2/3 has been clinically validated as a therapeutic target for both epilepsy and pain, with further encouraging clinical data in depression. Its ETX-123 lead candidate is an generate new chemical entities designed to harness the efficacy of the Kv7.2/3 channel mechanism while attempting to improve the safety and tolerability relative to earlier molecules, based on its insights into the mechanisms of toxicity and the potency and selectivity profile.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
  1. Stock
  2. Equities
  3. Stock Eliem Therapeutics, Inc. - Nasdaq